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Estrogen metabolites have been implicated in rheumatoid arthritis (RA) and cancer, although the mechanism remains
unestablished. Some estrogen metabolites, which are used for the assessment of cancer risk, play an important role in RA. The
pathways by which malignancies associated with RA remain elusive. Possible mechanism involves enzymatic or nonenzymatic
oxidation of estrogen into catecholestrogen metabolites through semiquinone and quinone redox cycle to produce free radicals
that can cause DNAmodifications. Modifications of DNA alter its immunogenicity and trigger various immune responses leading
to elevated levels of cancer and RA antibodies. However, the role of different estrogenmetabolites as amediator of immune response
cannot be ruled out in various immune-related diseases.
1. Introduction
The associations of malignancy with autoimmune rheumatic
diseases have been well established, but none of the stud-
ies reported any evidence regarding the role of estrogen
metabolites in cancer morbidities in RA patients. It has
been found that certain cancers are more common, some
are less common, and some are the same as for non-RA
population. It is interesting to know that measurement of
some estrogen metabolites for the assessment of cancer risk
could play important role in RA. RA is an autoimmune
condition in which dysregulated lymphocytes react against
self-antigens by producing autoantibodies, and the normal
immune function is suppressed [1]. Dysregulations of the
host’s immune surveillance aswell as immunosuppression are
the risk factors for different types of cancer [2]. RA has been
known to increase the risk of lymphoma [3] along with other
types of cancer.These patients are at high risk for lymphoma,
while lymphoma patients are not at high risk for RA. And the
more severe the RA is, the higher the risk of lymphoma is. In
addition, there are almost 8 different types of cancer linked to
RA, which may be caused by RA medications or RA-related
inflammation itself. These include lung, skin, myeloma,
non-Hodgkin’s lymphoma and Hodgkin’s disease, lymphoma
linked to TNF inhibitors, leukemia, breast, colorectal, and
prostate cancers.
Previous studies have shown that there is a significant
association between RA and subsequent development of lym-
phoproliferative malignancy [4]. These malignancies include
many different disease entities with distinct cells of origin,
pathologies, risk factor profiles, and prognosis [5]. Lym-
phomas have been classified into Hodgkin’s lymphoma (HL)
and non-Hodgkin’s lymphoma (NHL) including multiple
subtypes such as follicular lymphoma (FL), leukemia (CLL),
and lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s
macroglobulinemia (WM). Although the causes of these
lymphoproliferative malignancies are mostly unknown, data
support a role for genetic and immune-related factors in their
pathogenesis [6].
Earlier evidence has shown that there is an increased risk
of serious infections and a dose-dependent increased risk of
malignancy in RA patients treated with anti-TNF antibody
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therapy [7]. Although the malignancies reported in these
trials are rare, comparing patients treatedwith anti-TNF ther-
apies versus patients receiving methotrexate or no disease-
modifying antirheumatic drugs suggested an increased risk of
hematological malignancies in anti-TNF treated patients [8].
In addition, an increased risk of nonmelanoma skin cancers
has been reported in patients with RA treated with anti-TNF
agents in combination with methotrexate [9]. Furthermore, a
dose-dependent increase in the risk of malignancies should
be taken in account when considering anti-TNF antibody
treatment in patients with RA.
Estrogens and their metabolites play an important role
in autoimmune rheumatic diseases [10] and cancer [11, 12].
Estrogen has not only anti-inflammatory but also proinflam-
matory roles depending upon different influencing factors
[13]. Even the downstream metabolites of estrogen were
shown to have important effects relevant to inflammation.
Estrogen metabolites are also associated with different types
of cancer, and these metabolites could provide a convenient
marker either of increased risk of cancer or of early cancer, if
altered levels precede the onset of clinical disease.
Currently, the exact causes of cancer morbidities in RA
aremostly unknown; however, data support a role of estrogen
metabolites in cancer morbidities in RA patients. In this
paper, we will review the findings from studies on this
topic and discuss the possible role of estrogen metabolites
(catecholestrogen and other active metabolites) in different
types of malignancies associated with RA. Furthermore, we
discuss that the same mechanism is operated both in RA
and cancer, as the data suggested the production of estrogen
metabolites induced reactive oxygen species (ROS), which
couldmodifyDNAand produce different immune responses.
2. Estrogen Metabolites
Estrogen is a hormone group that comprises estrone, estra-
diol, and estriol. It has been hypothesized that the initiation of
cancer may result from induction of DNA damage by estro-
gen metabolites, although progression may be facilitated by
estrogen receptor-mediated upregulation of mitogenic genes.
There are various reports that confirm that estrogen metabo-
lites are tumorigenic in animal model [14, 15]. Estradiol and
estrone undergo extensive oxidative metabolism via action
of several cytochromes P450 (mainly CYP1A1 and CYP1B1).
These are major enzymes catalyzing 𝛽-nicotinamide ade-
nine dinucleotide phosphate (NADPH) dependent oxidative
metabolism of estrogen tomultiple hydroxylatedmetabolites.
Each cytochrome P450 favours the hydroxylation of specific
carbons, although, cytochrome enzymes can hydroxylate
virtually all carbons with the exception of the inaccessible
angular carbon. Liver microsomes from adult rats resulted
in the formation of up to 20 detectable estrogen metabolites
when incubated with [4- 14C] estradiol andNADPH [16].The
generation of hydroxyl and keto functions at specific sites of
the steroid nucleus markedly affects the biological properties
of the respective estrogen metabolites whether the reaction
yields estrogenic, nonestrogenic, or carcinogenicmetabolites.
Functionally, the most important reactions catalyzed by
cytochrome P450 are at carbon 2, 4, and 16.
Catecholestrogens are biologically active metabolites of
estrogen which are synthesized by enzyme 2- and 4-
hydroxylase in the liver, brain, and other organs [17].They are
generated by actions of genes encoded by CYP1A1, CYP1A2
(which catalyze 2-hydroxylation of estrogens), and CYP1B1,
which are having 4-hydroxylase activity. Specifically, CYP1A1
converts estradiol firstly to 2-hydroxyestradiol (2-OHE
2
) and
then to the estradiol-2,3-semiquinone (E-2,3-SQ) and estra-
diol quinone (E-Q). CYP1B1 converts estradiol firstly to 2-
and 4-hydroxyestradiol (4-OHE
2
) and then to corresponding
semiquinone and quinones. 4-Hydroxyestrogens can oxidize
to quinone intermediates that can react with purine bases
of DNA, resulting in depurinating adduct that can generate
highly mutagenic apurinic sites. Quinones derived from the
2-hydroxyestrogen produce stable DNA adducts and are
presumed to be less genotoxic [18].The catecholestrogens also
serve as substrate for catechol-o-methyl transferase (COMT),
which catalyze o-methylation by formingmonomethyl ethers
at the 2-, 3-, and 4-hydroxyl groups [19]. COMT generated
two products from 2-hydroxyestrogens in contrast to the
single product from4-hydroxyestrogens [20].However, small
amount of catecholestrogenmay be converted by peroxidase-
catalyzed reaction to yield semiquinone or quinones that are
capable of forming DNA adducts or of generating ROS that
could oxidizeDNAbases [19]. 4-OHE
2
generates free radicals
through reductive-oxidative cycling, thus causingDNAdam-
age. In contrast to 4-hydroxyestrogens, 2-hydroxyestrogen
is not carcinogenic and has potent inhibitory effect on the
growth of tumor cells and on angiogenesis [21].
In human, cytochrome P450 3A7 has strong catalytic
activity for estrone 16 𝛼-hydroxylation [22]. Similar to the
catecholestrogen, the 16 𝛼-hydroxylated estrogens are hor-
monally active, chemically reactive, and potentially muta-
genic. 16𝛼-hydroxyestrone (16𝛼-OHE
1
) possesses the unique
property of binding covalently to the estrogen receptor and
other nuclear proteins, such as histones. Levels of 16 𝛼-
OHE
1
can rise in response to obesity, alcohol consumption,
and toxic exposure. High levels of this potent metabolite
are linked to increased risk and poorer prognosis in condi-
tions associated with estrogen excess, including cancer and
lupus.
As discussed already, the major metabolites of estradiol
and estrone are those hydroxylated at either the C-2 or the C-
16 positions. Hydroxylatedmetabolites at theC-4 position are
also present, but in lesser amount. However, the C-4 and C-
16 hydroxylated estrone or estradiol metabolites are different
from C-2 because these metabolites have more estrogenic
activity than that of their mother compound [23]. It has been
suggested that women who metabolize a large proportion
of their estrogen down the C-4 pathway, in contrast to the
C-2 pathway, have elevated breast cancer rates, while the
daughter estrogen metabolized down the C-16 route may be
associated with a direct genotoxic effect and carcinogenicity
[24]. Studies have found that if particular enzymes within
cytochrome family, namely, P450 1A1 and 1A2, are activated,
thenmore parent estrogens are metabolized into C-2 hydrox-
ylated compounds [25]. However, if cytochrome P450 3A4
and 1B1 are activated, then more C-4 and C-16 are produced
[26].
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3. Estrogen Metabolites and
Mutations in DNA
Endogenous estrogen can become carcinogenic via forma-
tion of catecholestrogen quinones, which react with DNA
to form specific depurinating estrogen-DNA adducts. Cat-
alytic oxidation of the catecholestrogens (2-hydroxy and 4-
hydroxyestrogens) gives rise to the corresponding estrogen-
2,3-quinone (E-2,3-Q) and estrogen-3,4-quinone (E-3,4-Q),
which react with DNA to form adducts [27]. These adducts
can form stable mutations that remain in the DNA unless
they are corrected by repair. Alternatively, the modified
bases can be released from DNA by destabilization of the
glycosidic bond and result in formation of depurinating or
depyrimidinated sites [27].
Few studies have reported the presence of catechole-
strogen adduct in human breast tissues [28, 29]. It has
been found that every DNA sample from these tissues
consists of deoxyguanosine adducts of 4-OHE
2
and 4-OHE
1
.
The formation of catecholestrogen quinone-derived DNA
adducts has also been reported in these two breast samples
[29], and the adducts identified were 4-hydroxyestradiol-
1-N3-adenosine, 4-hydroxyestrone-1-N3-adenosine, and 4-
hydroxyestradiol-1-N7-guanine. Treatment of E-3,4-Q with
dG also results in the formation of 4-hydroxyestradiol-1-
N7-guanosine [30]. The reaction of E-3,4-Q with dG at the
N-7 position destabilizes the glycosidic bond and results in
loss of the deoxyribose moiety. Once the adduct is formed
by reaction of E-3,4-Q with DNA, it is released from the
DNA by spontaneous depurination. In addition, injection
of 4-OHE
2
or E-3,4-Q in mammary glands of female ACI
rats resulted in formation of the depurinating adducts 4-
hydroxyestradiol-1-N3-adenosine and 4-hydroxyestradiol-1-
N7-guanosine [31]. Reaction of E-3,4-Q with dA produced
no adducts; however, its reactions with Ade resulted in the
formation of 4-hydroxyestradiol-1-N3 Ade [32].When E-3,4-
Q react with dG or dA, the adducts formed were identified
as 2-hydroxyestradiol-6-N2 dG and 2-hydroxyestradiol-6-N6
dA. DNA adducts derived from 2-hydroxyestrogen-quinone
have been shown to be mutagenic and primarily produced
G-T and A-T mutations in Simian kidney cells [33]. In
contrast to 2-hydroxyestrogen, E-3,4-Q reacts rapidly to
form 4-hydroxyestradiol-1-N3-adenosine adducts that are
depurinating adducts. Numerous A→G mutations in H-ras
DNA were observed in SENCAR mouse skin treated with E-
3,4-Q [34].
Estrogens induce lipid peroxidation during their meta-
bolic activation [35]. Lipid hydroperoxides formed dur-
ing estradiol metabolism may serve as cofactors in fur-
ther estradiol metabolism to hydroxylated products and in
the oxidation of catecholestrogen to quinone intermedia-
tes. In addition, lipid hydroperoxide-derived aldehydes (mal-
ondialdehyde and 4-hydroxynonenal) interact with bases
in cellular DNA, thus increasing the burden of DNA
modification [36]. Oxidative metabolism of estrogen meta-
bolites produced three types of DNA damage: DNA base
adducts produced by quinone, as describe above, lipid
hydroperoxide-derived aldehyde DNA adducts, and plethora
of oxidized DNA bases.
Earlier studies from our lab showed that estrogen
metabolites (especially catecholestrogen) cause single and
double strand breaks, change in the ellipticity of the double
helical DNA, and various other types of DNA modifications
[11, 37–40]. It is interesting to note that modification induced
by these catecholestrogen metabolites was the greatest for
thymine followed by guanine, adenine, and cytosine. In
addition, catecholestrogen metabolites cause more extensive
damage toDNA in presence of copper in comparison to nitric
oxide. These results demonstrate that catecholestrogen leads
to the production of potent ROS, which is capable of causing
DNA damage, thus playing important role in carcinogenesis
[11, 12] and various autoimmune diseases [37–40].
Mutations are caused by numeric changes or structural
alterations in the genome. Recent study has shown that
some estrogen metabolites are capable of producing genome
instability [41]. DNA modification by these reactive estrogen
metabolitesmight explain someof the structural andnumeric
chromosomal changes observed in response to estrogen
exposure [42]. In conclusion, estrogen metabolites can pro-
duce multiple types of genetic insults contributing to the
induction of genomic instability.
4. Estrogen Metabolites and Immune System
Sex hormones are implicated in the immune response, with
estrogen as enhancer of humoral immunity and androgens
as natural suppressor of the immune response [43]. Sex
biases in autoimmunity and infection, together with immune
cell expression of estrogen and androgen receptors, sug-
gest that sex steroid hormone directly modulates immune
cells [44]. Dual proinflammatory and anti-inflammatory
effects of estrogen in human and experimental inflammation
depend on various factors including intracellular conver-
sion of estrogen into active metabolites with quite different
pro-inflammatory and anti-inflammatory functions [13]. A
pro-inflammatory microenvironment leads to conversion of
androgen to estradiol and downstream estrogens [45], that
are further converted to 16-hydroxylated active estrogens but
not to 2-hydroxylated endogenous antiestrogens [46]. A shift
from 2-hydroxyestrogens to 4-hydroxyestrogens might be an
additional pro-inflammatory signal because these estrogen
metabolites can be converted to 3,4-quinones, which are
capable of damaging DNA leading to depurination and
mutation in vivo [31]. Similarly, a shift to 16 𝛼-hydroxylated
forms of estrogen can be an important pro-inflammatory
and proliferative signal [10, 13]. In contrast to the prooxidant
activities of 4-OHE
2
, 2-OHE
2
is a potent antioxidant that
prevents membrane phospholipids and cells against ROS
[47]. Thus 4-OHE
2
in comparison to 2-OHE
2
induces car-
cinogenic and pro-inflammatory effects [48]. Presently, we do
not knowwhether pro-inflammatorymediator induces a shift
from 2-hydroxyestrogen to 4- and 16-hydroxylated estrogens.
Estradiol increased IgG and IgM production by periph-
eral blood mononuclear cells (PBMC) in patients who had
systemic lupus erythematosus (SLE). This led to elevated
levels of polyclonal IgG, including IgG anti-dsDNA, by
enhancing B-cell activity via IL-10 [49]. Estrogen can also
4 BioMed Research International
modulates pro-inflammatory cytokines released from acti-
vated monocytes or macrophages, in particular through the
modulation of CD 16 expression [50]. It was recently shown
that disease activity in patients who had SLE correlated nega-
tively with urinary concentration of 2-hydroxylated estrogens
[10]. Hence estrogens are confirmed as one of the risk factors
for autoimmunity.
The possible roles of downstream metabolites of estrone
and estradiol were shown to have important effects rele-
vant to inflammation. The growth inhibiting effects of 2-
OHE
2
and 2-methoxyestradiol come into limelight, several
of these effects are independent of ERs, and relatively
high concentrations of hormone were used [46, 48]. 2-
Methoxyestradiol inhibited endothelial cell proliferation and
migration aswell as angiogenesis in vitro [51]. Because neoan-
giogenesis is an important mechanism in inflammation, 𝛼-
methoxyestradiol can exert anti-inflammatory activities by
inhibiting vessel formation. These lines of evidence showed
that 2-methoxyestradiol is a proapoptotic and cytostatic
endogenous compound, which can inhibit neoangiogenesis
and can attenuate inflammation. In contrast, 4-hydroxylated
estrogens might exert pro-inflammatory roles by inducing
ROS and DNA damage.
One of the important properties of estradiol is its ability
to differentiate T and B cells, increase immunoglobulin pro-
duction, and aggravate immune complex mediated diseases
[52]. Immunoglobulin production was also seen in those
patients who are diagnosed with breast cancer [53]. These
studies are in agreement with our previous studies that
explain the presence of antibodies against catecholestrogen-
modified DNA (CE-DNA) in the sera of cancer [11, 12], SLE
[37–39], and RA patients [40]. Studies from our laboratory
demonstrate that catecholestrogens are likely to contribute to
the generation of antibodies which may directly or indirectly
affect the immune system.
Estrogen and some of its metabolites (estradiol, estrone,
16 𝛼-OHE
1
, and estriol) may induce myeloperoxidase release
from the resting cells and stimulate generation of oxidants
[54]. 2-hydroxylated estrogen acts as powerful inhibitors
of PMNs (polymorphonuclear leukocytes, neutrophils, and
granulocytes) activity, which show protective properties of
the 2-hydroxylated catecholestrogen. In addition, estrogen
causes macrophage proliferation and activation, and in turn
macrophages produce estrogens, which may act on other
phagocytic cells. Hence, macrophages activation may lead to
ROS production, which may cause DNA base hydroxylation,
oxidation, nitration, and deamination. In conclusion, estro-
gens and their metabolites affect inflammatory responses,
and in turn, their activities are controlled by different inflam-
matory products.
5. Role of Estrogen Metabolites in
Cancer Morbidity in RA
Patients with RA have double the risk of death from the
disease compared to the general population. Conclusions
about whether RA patients are more likely to die from
cancer than the general population have been less clear.Many
studies have confirmed that although rates of over all cancer
are not increased substantially from the general population,
certain types of cancers may be seen with higher frequency
in patients with RA [9, 55]. Most commonly, an increased
risk for development of lymphoproliferative disorders, partic-
ularly non-Hodgkin’s lymphoma, has been shown in patients
with RA [56]. It is unclear whether the increased risk is due to
aberrancies in the immune system from higher inflammatory
activity in RA, from certain immunosuppressive agents used
to treat RA, or from a combination of the both [57]. It has
been suggested that an increase risk for the development
of nonmelanoma skin cancers (NMSC), such as basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC), was
observed in patients with RA when compared to its rate
in the general population [58]. The association between RA
and malignancies has received increased attention in recent
years. Reports suggested that tumor necrosis factors (TNFs)
blockers might elevate the risk of malignancy in RA patients
[58].There is a relationship between the level of inflammation
in RA patients and their risk of developing lymphoma.
This risk might be magnified by knowing the various roles
played by different types of estrogen metabolites in cancer
morbidities in RA.Overall, the clinical relevance of these data
regarding RA and malignancy is unclear.
Estrogen metabolites are known to play an important
roles in various autoimmune diseases (especially RA) [10,
37–40, 59] and cancer [11, 12]. In patients with RA and
SLE, urinary concentration of the downstream mitogenic 16
𝛼-OHE
1
and 2-OHE
1
or naturally occurring antiestrogen
was investigated. These studies have shown that urinary
concentrations of the 2-hydroxylated estrogens were 10 times
lower in patients with RA and SLE than those in healthy
control, whereas the ratio of 16 𝛼-OHE
1
/2-hydroxyestrogen
was 20 times higher in RA and SLE patients than that
in control [10]. These results showed that the magnitude
of conversion to the mitogenic 16 𝛼-OHE
1
is extremely
upregulated in RA and SLE. Testing for urinary levels of 2-
OHE
1
and 16 𝛼-OHE
1
provides valuable insight regarding the
assessment for cancer risk [60]. The ratio of 2-OHE
1
to 16 𝛼-
OHE
1
(or estrogen metabolic index (EMI)) should be greater
than 2 and values in the upper normal range are advisable.
Women with breast and endometrial cancers have marked
elevation of 16 𝛼-OHE
1
, which is a significant risk factor for
estrogen-dependent tumor [61]. Tumors in other estrogen-
sensitive tissues are also linked to 16 𝛼-OHE
1
. It has been
found that the ratio of 2-OHE
1
to 16 𝛼-OHE
1
is a risk factor
not only for breast cancer but also for other conditions of
inappropriate estrogen activity. 16 𝛼-OHE
1
is amitogenic and
proliferative endogenous hormone that covalently binds to
estrogen receptor leading to nuclear translocation [62]. This
metabolite is converted from upstream estrone and estradiol,
and because of this covalent linkage to the receptor, it
shows persistent biological responses consisting of mitogenic
tumor stimulation [63]. 2-OHE
1
is essentially devoid of
peripheral biological activity, has been found to exert a
modest antiestrogenic effect [60], and considered as “good
estrogen” [64]. In addition, 16 𝛼-OHE
1
has been found to
be elevated in those at risk for breast cancer as well as other
conditions associated with hyperimmune activity such as
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RA and SLE. In these conditions, 16 𝛼-OHE
1
was 10 times
higher in the control population [10]. Therefore, estrogen
metabolism should be taken into considerationwhen treating
patients with autoimmune conditions.
Elevated serum concentration of 16 𝛼-OHE
1
has been
described in patients with SLE [65], suggesting that abnormal
patterns of estradiol metabolismmay lead to increased estro-
genic activity. A similar phenomenon was recently described
in the synovial fluids (SFs) of RA patients, where 16 𝛼-
OHE
1
and 4-OHE
2
were found to be significantly higher
compared with control fluid [45]. Interestingly, women who
developed knee osteoarthritis, which is also an inflamma-
tory disease, were more likely to have a ratio of 16 𝛼-
OHE
1
to 2-OHE
1
in highest tertile and 2-hydroxyestrogen
in the lowest tertile [66]. The loss of 2-hydroxyestrogen
is obviously a pro-inflammatory signal, which might be
unfavorable in breast cancer development. Catecholestrogen,
2-OHE
2
, and 4-OHE
2
have been demonstrated to induce
uterine adenocarcinoma in the CD-1 mouse model [14].
2-Hydroxylated metabolites of estrogen have been shown
to have antiangiogenic effects and inhibit tumor cell pro-
liferation, whereas 4-hydroxylated metabolites are known
to be implicated in carcinogenesis. In addition, estradiol
and 4-OHE
2
are mutagenic even at lowest dose, whereas
2-OHE
2
induced mutation at very high concentration. In
animal model, 4-OHE
2
had a carcinogenic effect equal to
that of estradiol, whereas 2-OHE
2
did not induce kidney
tumors in hamsters [67] and had much less ability to induce
uterine adenocarcinoma in CD-1 mice than did 4-OHE
2
[14].
Furthermore, the formation of depurinating adducts, by the
reaction of E-3,4-Q enzymes-catalyzed oxidation of 4-OHE
2
with DNA, is much higher than that from reaction of E-2,3-
Q enzymes-catalyzed oxidation of 2-OHE
2
with DNA [68].
Interestingly, the 4-hydroxylated estrogens were 3.5 times
more abundant than the 2-hydroxylated estrogen in women
with breast cancer andwere 4 times higher in womenwithout
breast cancer [69]. The rate of 4-OHE
2
formation exceeded
those of 2-OHE
2
formation by almost 4 fold in mammary
fibroadenomas and adenocarcinoma, although the rate did
not markedly differ in normal human mammary tissues [15].
Besides various studies investigating urinary concentra-
tion of the downstream mitogenic estrogen metabolites (16
𝛼-OHE
1
, 2-OHE
2
, and 4-OHE
2
) in cancer [60] and autoim-
mune diseases [10], data from our laboratory demonstrate
that estrogen metabolites especially catecholestrogens (2-
and 4-hydroxylated estrogens) play important role in cancer
[11, 12] as well as in various autoimmune diseases including
RA [37–40]. It has been found that CE-DNA was highly
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recognized not only by circulating cancer autoantibodies
[11, 12] but also by RA [40] and SLE autoantibodies [37–
39], indicating the possible participation of CE-DNA in the
pathogenesis of cancer and RA. It is interesting to note that
single antigen (CE-DNA) is known to play dual role in the
etiopathogenesis of RA and cancer, and that might be the
reason that cancer morbidities are common in RA. Since
native DNA is a known weak immunogen, it appears that
DNA damage by catecholestrogen renders it immunogenic
leading to the induction of RA and cancer autoantibodies.
The recognition of CE-DNA by autoantibodies in cancer and
RA was further evaluated by quantitative precipitin titration,
and it was found that high values of affinity constant clearly
indicate better recognition of CE-DNA by these circulating
cancer and RA autoantibodies [11, 12, 40], and hence prove
the hypothesis that malignancies are associated with RA.
The intracrine synthesis of active estrogen metabolites at
the level of cells was involved in the immune response
(e.g. synovial macrophages and fibroblasts) [70]. In addition,
recent findings indicate that RA synovial cellsmainly produce
the proproliferative 16alphaOH-estrone, which, in addition
to 16alphaOH-17beta-estradiol, is one of the only 2 estrogens
studied that does not inhibit TNF secretion. A preponderance
of 16alpha-hydroxylated estrogens is an unfavorable sign in
synovial inflammation. Women at high risk of breast cancer,
thosewith benign breast disease and thosewho are diagnosed
with breast cancer, have significantly elevated anti-HMdU
(5-hydroxymethyl-2󸀠-deoxyuridine) autoantibodies [53].The
presence of high anti-HMdU autoantibodies levels explains
the prooxidant conditions that have lead to oxidation of
bases in cellular DNA and have evoked an autoimmune
response just like RA in our previous study [40]. These
reports suggest that the oxidative DNA base damage and
the biologic responses it evokes start occurring not only
in carcinogenesis but also in RA. These results are further
strengthened by data obtained from our study and by other
investigators that showed that oxidative DNA base damage is
evident in DNA of individuals who are at risk for hormone-
dependent cancers [53] and RA [40]. These studies show
that estrogenmetabolites might play important role in cancer
morbidities in RA.
6. Conclusion
The association between RA and malignancies has been well
established, but the exact mechanism for carcinogenesis in
RA is lacking. Estrogen metabolites seem to play an impor-
tant role in RA and cancer, but the mechanisms that connect
these two conditions are missing. It is obvious that we must
consider not only the parent estrogen when we evaluate dis-
ease risk (RA and cancer) but also the estrogen metabolites.
While we do not have the full picture of all the responsible
factors involved in cancer morbidity in RA, data indicate that
oxidative reactions, catalyzed by isoform of the cytochrome
P450, can result in the formation of catecholestrogens from
the parent compound, and quinone/semiquinone redox cycle
of the catecholestrogen metabolites is capable of forming
either stable or depurinating DNA adducts. Oxidation of
these estrogen metabolites also leads to high amount of ROS
that can cause extensive DNA damage. This would proba-
bly alter its immunogenicity leading to the induction and
elevated levels of RA and cancer autoantibodies (Figure 1).
Estrogen is known to play both pro- and anti-inflammatory
roles that were found to be related to the intracellular con-
version into active metabolites with different pro- and anti-
inflammatory functions. Particular lines of evidence related
to estrogen administrate seem to support those effects. Since
17beta-estradiol administered during hormone replacement
therapy (i.e. early menopause, endometriosis, etc...) in RA
patients will rapidly increase estrone sulfate after conver-
sion in adipose tissue by aromatases, hormone replacement
therapy can have proinflammatory and cell proliferative
effects by providing estrone sulfate to the inflamed synovial
tissue. In addition, it appears that the use of combined oral
contraceptives is associated with an increased risk of at least
systemic lupus erythematosus (disease flare up, worsening,
etc...) [71]. So estrogen modulates immune response by
affecting various inflammatory responses, and in turn, their
activities are affected by these inflammatory products. Only
by understanding the complex interaction of various estrogen
metabolites and mechanism behind these two pathological
conditions, we will be able to manage cancer morbidities in
RA.
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